Detecting PDAC at the earliest stages (I and II), when surgical interventions are possible, can greatly improve patient outcomes. According to the American Cancer Society, the survival rate for patients diagnosed at stages III and IV is 3%. If detected earlier, at stage I or II, the 5-year survival rate jumps to 42%.
Currently, only about 13% of patients are diagnosed with stage I or II pancreatic cancer; 47% of patients are diagnosed at stage III or IV.
Immunovia, Inc.’s goal with the IMMray® PanCan-d test is to detect PDAC at earlier stages (stage I and II), when interventions and treatments can be more effective.
American Cancer Society. Cancer Facts and Figures 2022.
American Cancer Society (pdf)
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(1):7-33. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21654. Accessed January 18,2022.